Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 65 views

    TRANSLATED

    Uploaded by

    JamieAkhmad
    The document discusses how monoclonal antibodies (MAbs) targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein show potential as a treatment for COVID-19, as cross-neutralizing SARS-CoV RBD-specific MAbs have shown effectiveness against related coronaviruses. Appropriate RBD-specific MAbs could be identified by analyzing the similarity between the RBD of SARS-CoV-2 and SARS-CoV. Combination therapy with RBD-targeting MAbs and the drug remdesivir may provide an ideal treatment option for COVID-19.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    TRANSLATED

    Uploaded by

    JamieAkhmad
    65 views4 pages
    The document discusses how monoclonal antibodies (MAbs) targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein show potential as a treatment for COVID-19, as cross-neutralizing SARS-CoV RBD-specific MAbs have shown effectiveness against related coronaviruses. Appropriate RBD-specific MAbs could be identified by analyzing the similarity between the RBD of SARS-CoV-2 and SARS-CoV. Combination therapy with RBD-targeting MAbs and the drug remdesivir may provide an ideal treatment option for COVID-19.

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The document discusses how monoclonal antibodies (MAbs) targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein show potential as a treatment for COVID-19, as cross-neutralizing SARS-CoV RBD-specific MAbs have shown effectiveness against related coronaviruses. Appropriate RBD-specific MAbs could be identified by analyzing the similarity between the RBD of SARS-CoV-2 and SARS-CoV. Combination therapy with RBD-targeting MAbs and the drug remdesivir may provide an ideal treatment option for COVID-19.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    65 views4 pages

    TRANSLATED

    Uploaded by

    JamieAkhmad
    The document discusses how monoclonal antibodies (MAbs) targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein show potential as a treatment for COVID-19, as cross-neutralizing SARS-CoV RBD-specific MAbs have shown effectiveness against related coronaviruses. Appropriate RBD-specific MAbs could be identified by analyzing the similarity between the RBD of SARS-CoV-2 and SARS-CoV. Combination therapy with RBD-targeting MAbs and the drug remdesivir may provide an ideal treatment option for COVID-19.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 4

    category A agents (cholera, plague).

    Patients should be placed in separate


    rooms or cohorted together. Negative
    pressure rooms are not generally
    needed. The rooms and surfaces and
    equipment should undergo regular
    decontamination preferably with
    sodium hypochlorite. Healthcare
    workers should be provided with fit
    tested N95 respirators and protective
    suits and goggles. Airborne
    transmission precautions should be
    taken during aerosol generating
    procedures such as intubation, suction
    and tracheostomies. All contacts
    including healthcare workers should
    be monitored for development of
    symptoms of COVID-19. Patients can be
    discharged from isolation once they
    are afebrile for at least 3d and have
    two consecutive negative molecular
    tests at 1 d sampling interval. This
    recommendation is different from
    pandemic flu where patients were
    • All clinicians should keep
    themselves updated about recent
    developments including global
    spread of the disease.

    • Non-essential international travel


    should be avoided at this time.

    • People should stop spreading


    myths and false information about
    the disease and try to allay panic
    and anxiety of the public.

    Conclusions

    This new virus outbreak has


    challenged the economic, medical and
    public health infrastructure of China
    and to some extent, of other countries
    especially, its neighbors. Time alone
    will tell how the virus will impact our
    lives here in India. More so, future
    outbreaks of viruses and pathogens of
    zoonotic origin are likely to continue.
    Therefore, apart from curbing this
    outbreak. efforts should he made to
    considerable protection in mice against a MERS-
    CoV lethal challenge. Such antibodies may play a
    crucial role in enhancing protective humoral
    responses against the emerging CoVs by aiming
    appropriate epitopes and functions of the S protein.
    The cross-neutralization ability of SARS-CoV RBD-
    specific neutralizing MAbs considerably relies on
    the resemblance between their RBDs, therefore,
    SARS-CoV RBD-specific antibodies could cross-
    neutralized SL CovVs, i.e., bat-SL-CoV strain WIVI1
    (RBD with eight amino acid differences from SARS-
    CoV) but not bat-SL-CoV strain SHC014 (24 amino
    acid differences) (200).

    Appropriate RBD-specifie MAbs can be


    recognized by a relative analysis of RBD of SARS-
    CoV-2 to that of SARS-COV, and cross-neutralizing
    SARS-CoV RBD-specific MAbs could be explored
    for their effectiveness against COVID-19 and further
    need to be assessed clinically, The U.S.
    biotechnology company Regeneron is attempting to
    recognize potent and specific MAbs to combat
    COVID-19. An ideal therapeutic option suggested
    for SARS-CoV-2 (COVID-19) is the combination
    therapy comprised of MAbs and the drug remdesivir
    (COVID-19) (201). The SARS-CoV-specific human
    MAb CR3022 is found to bind with SARS-CoV-2
    RBD, indicating its potential as a therapeutic agent

    You might also like